Some chemotherapy regimens include agents that are mutagenic or clastogenic in model systems. This raises concerns that cancer survivors who were treated before or during their reproductive years may be at increased risks for abnormal reproductive outcomes. However, the available data from offspring of cancer survivors are limited, representing diverse cancers, therapies, time to pregnancies, and reproductive outcomes. Rodent breeding data after paternal exposures to individual chemotherapeutic agents illustrate the complexity of factors that infl uence the risk for transmitted genetic damage including agent, dose, end point, and germ cell susceptibility profi les that vary across agents. Direct measurements of chromosomal abnormalities in sperm of mice and humans by sperm fl uorescent in situ hybridization have corroborated the differences in germ cell susceptibilities. The available evidence indicates that the risk of producing chromosomally defective sperm is highest during the fi rst few weeks after the end of chemotherapy and decays with time. Thus, sperm samples provided immediately after the initiation of cancer therapies may contain treatment-induced genetic defects that will jeopardize the genetic health of offspring.
tations ( 11 ) : they include patients who received both mutagenic and nonmutagenic regimens with broad differences in drug regimens, doses, exposure duration, and so forth, with small numbers of children born to survivors of any specifi c treatment regimen; the end points evaluated in pregnancies and offspring have been diverse, with few data for any one end point; and most patients were treated as children so that pregnancies under investigation occurred long after treatment and do not refl ect pregnancies that may result from exposure to germ cells at more sensitive time windows of gametogenesis. These variables have precluded reliable estimates of relative reproductive risks for survivors of treatment with specifi c chemotherapeutic agents.
The generally negative human offspring data need to be better reconciled with the generally positive data for mouse breeding studies, as well as rodent and human sperm fl uorescent in situ hybridization (FISH) assays for induced chromosomal abnormalities. The purpose of this article is to provide a brief overview of the rodent breeding data for heritable effects after paternal exposure to chemotherapeutic agents and of the human and rodent data for chemotherapy-induced chromosomal abnormalities in sperm and to identify areas for additional research and clinical recommendations regarding germ cell susceptibilities after cancer chemotherapy.
S PERMATOGENESIS AND T YPES OF G ENETIC D AMAGE T RANSMITTED VIA S PERM
Spermatogenesis is a highly regulated differentiating system, both temporally and spatially. The spermatogenic stem cells differentiate through division of spermatogonia (mitotic divisions) to form spermatocytes (meiotic cells) that undergo two meiotic divisions to give rise to spermatids (haploid postmeiotic cells) that mature into functional sperm. The kinetics of spermatogenesis are well established for men and several mammalian species ( 12 ) and are remarkably constant within species, so that the time between treatment and sampling of sperm can be used as a surrogate for sampling effects of chemotherapy on specifi c spermatogenic cell types. The longer the time interval between treatment and sampling, the earlier in spermatogenesis the effects are being sampled.
Physiological damage of chemotherapy to male germ cells, which has been strongly associated with fertility, is primarily monitored by parameters of semen quality. Exposure to more than 100 chemicals, individually or as mixtures and including chemotherapeutics, is known to induce detrimental effects on sperm morphology, number, and motility ( 13 ) . However, we understand very little about the effects of chemotherapy on the mechanisms and frequency of sperm defects that might increase the risks of genetic or chromosomal abnormalities among offspring ( Table 1 ) ( 14 ) . Sperm defects induced by chemotherapy in model systems include whole and segmental chromosomal aneuploidies that can results in complete or partial trisomy in offspring, respectively. The molecular targets for whole chromosomal aneuploidy (e.g., centromere, microtubules, and chromosome pairing) are not thought to involve mutational mechanisms. De novo segmental aneuploidy in germ cells, however, involves double-strand DNA breaks that can arise spontaneously, especially in postmeiotic cells ( 15 ) , or that can be induced by exposure to mutagens ( 16 , 17 ) .
Sperm carrying defects in the imprinting profi les are theoretically important because altered expression of a paternal gene during critical stages of development might result in abnormal development or defects. Trinucleotide repeat length variation appears to be inducible in male germ cells after exposures to ionizing radiation ( 18 ) or environmental pollution ( 19 ) , but there is no information on the effects of chemotherapeutic agents. More research will be needed to understand the underlying mechanisms of induction and their heritable consequences.
A NIMALS B REEDING T ESTS FOR H ERITABLE E FFECTS OF C HEMOTHERAPEUTIC A GENTS
As most dramatically demonstrated in rodents, when males are treated with a mutagen and mated with unexposed females, the deleterious effects on reproduction can be profound, including infertility, lethality during development, and heritable chromosomal translocations, malformations, or cancer among offspring. Over the past 40 years, more than 30 chemicals have been tested in mice for germ cell mutagenicity, using three major tests ( 2 , 20 ) : dominant lethal, heritable translocation, and specifi c locus mutation. Dominant lethal measures the induction of unstable chromosomal aberrations that lead to the embryonic death of the progeny of treated males; however, other genetic and epigenetic mechanisms cannot be excluded. The heritable translocation and specifi c locus mutation tests measure the induction of chromosomal reciprocal translocations and gene mutations in the offspring of treated males, respectively. Table 2 lists the chemotherapeutic agents that have been tested in at least two of these breeding tests [ see ( 2 ) for an indepth discussion of all the germ cell mutagenicity results with chemotherapeutic agents].
Several points can be drawn from these studies regarding differential susceptibilities of male germ cells to chemotherapeutic agents. First, mutagenic chemotherapies generally induce a wide spectrum of lesions, resulting in various chromosomal abnormalities or gene mutations. Second, most chemotherapeutic drugs induce positive results in all three tests. One notable exception is 6-mercaptopurine, which affected only preleptotene spermatocytes, inducing dominant lethal but not heritable translocation or specifi c locus mutation ( 21 ) . Third, there are differences among the various phases of spermatogenesis in the sensitivity of induction of transmissible genetic damage. With the exception of etoposide, all treatments produced the highest response, if not the only response, in postmeiotic cells. The high sensitivity of postmeiotic cells is probably related to the reduced DNA repair capacity of late spermatids and sperm when compared with early spermatids and the other spermatogenic cell types ( 22 ) . Therefore, unrepaired DNA damage induced in these late stages of spermatogenesis may be transmitted. Also, protamines -basic proteins that replace histones during postmeiosis ( 26 , 27 ) . Although much has been learned from rodent breeding tests, they are very expensive, requiring thousands of animals, and they provide little information on the underlying mechanisms of action. Below, we describe two additional techniques (zygote cytogenetics and sperm FISH) as direct methods for investigating germ cell sensitivity profi les and mechanisms of action that may lead to abnormal reproductive outcomes after chemotherapy.
M OUSE PAINT/DAPI A SSAY FOR T RANSMITTED C HROMOSOMAL A BNORMALITIES
The metaphase plate of mouse fi rst-cleavage zygotes provides the fi rst opportunity ( 28 -30 ) for detecting cytogenetic defects in parental chromosomes after fertilization. We improved the classic cytogenetic analysis of mouse zygotes by combining 4´-6-diamidino-2-phenylindole (DAPI) staining with chromosomespecifi c painting probes (PAINT) for the simultaneous detection of numerical as well as stable and unstable chromosomal aberrations ( 31 ) . The PAINT/DAPI procedure was recently used to demonstrate that therapeutic doses of etoposide affected primarily male meiotic germ cells, producing unstable structural aberrations and aneuploidy -effects that were transmitted to the progeny ( 32 ) . This was the fi rst report of an agent for which paternal exposure led to an increased incidence of aneuploidy in the offspring.
The PAINT/DAPI method has been used for investigating germ cell stage susceptibility, the pattern of chromosomal aberrations in the zygote, and the type of abnormal reproductive outcomes induced by various mutagens, including the chemotherapeutic agents, cyclophosphamide, etoposide, and melphalan ( 27 ) . These studies have confi rmed the high sensitivity of male postmeiotic germ cells to mutagens and have shown that induced chromosomal damage and premutational lesions are carried to the zygote, where they are converted into chromosomal abnormalities that are associated with specifi c abnormal reproductive outcomes in terms of the germ cell stage sensitivity, proportion of affected zygotes, and types of outcomes.
I NFORMATION O BTAINED FROM H UMAN S PERM FISH A SSAYS
During the 1990s, FISH technology was adapted for the detection of chromosomally defective sperm, and its relevance has improved with the availability of chromosome-specifi c DNA probes for clinically relevant aneuploid syndromes (i.e., 21, 18, 13, X, and Y) ( 4 ) . Using sperm FISH, small exposure effects can be detected by studying large numbers of sperm in small number of patients. New sperm FISH methods have been recently developed for the detection of aneuploidy as well as structural aberrations ( 33 ) , but essentially all of the information for chemotherapeutic effects is limited to aneuploidy outcomes ( Table 3 ) .
In one of the larger studies, Robbins et al. ( 3 ) used an X-Y-8 sperm-FISH assay to study eight cancer patients treated with Novantrone, Oncovin, Velban, and Prednisone (NOVP) chemotherapy and found an approximate fi vefold increase in sperm with disomies and diploidies. The aneuploidy effects were transient, however, declining to pretreatment levels within about 100 days after the end of the therapy. Another analysis of NOVP patients using an X-Y-21 -18 sperm FISH assay found signifi cant, yet also transient, two-to 14-fold inductions for the most clinically relevant sperm aneuploidies, indicating that NOVP therapy increased the risk of fathering a child with any one of the major clinical aneuploidy syndromes ( 4 ) . A signifi cant increase in the frequency of diploidy and disomy for chromosomes 16, 18 , and XY was induced in testicular cancer patients treated with the cisplatin, etoposide, and bleomycin (PEB) regimen ( 34 ) . In a study of the effects of bleomycin, etoposide, and cisplatin (BEP) chemotherapy, sperm from eight testicular cancer patients were assessed both before and 2 -13 years after treatment ( 35 ) , showing no signifi cant treatment-related increase in the frequency of chromosomal abnormalities. In a different study, sperm chromosomal abnormalities were assessed in cancer patients before, during, and after BEP therapy, using probes for chromosomes 1, 12, X, and Y ( 36 ) , showing a signifi cant increase in the frequency of XY disomic sperm with treatment. Taken together, these limited data are consistent with the statement that treatment-induced aneuploidy effects in sperm, when they occur, are transient, with no long-term effects. However, the generality of this statement is unknown, because so few treatment regimens have been evaluated for sperm aneuploidy, and essentially none have been evaluated for treatment-induced chromosomal structural aberrations in sperm.
I NFORMATION F ROM M OUSE S PERM FISH S TUDIES
Most chemotherapeutic regimens consist of combination of drugs. Therefore, animal models were developed to evaluate the relative risk of individual drugs for the induction of genetic and chromosomal damage in sperm. Several multicolor sperm FISH assays have been developed to detect numerical abnormalities and chromosome structural aberrations in mouse sperm ( 37 , 38 ) . However, to date, only four chemotherapeutics have been studied with the mouse sperm-FISH assay for aneuploidy and diploidy induction. As shown in Table 4 , paclitaxel (Taxol) was tested at the maximum tolerated dose, and the increase of disomic sperm was marginally signifi cant ( 39 ) , vinblastine gave inconclusive results in repeated experiments in an interlaboratory comparison ( 40 ) , and etoposide and merbarone, both topoisomerase II inhibitors, showed signifi cant increases in the frequencies of diploid and hyperhaploid sperm ( 41 ) .
Etoposide is currently the only agent for which it is possible to compare the response to chemotherapeutic agents between rodents and humans. It induced signifi cant increases in the frequencies of diploid and aneuploid sperm of both mice ( 41 ) and young human patients ( 34 ) .
E VIDENCE FOR S USCEPTIBILITIES OF D IFFERENTIATING M ALE G ERM C ELLS TO C HEMOTHERAPIES AND C LINICAL I MPLICATIONS
The evidence from sperm, zygote, and breeding studies demonstrates that chemotherapy can induce signifi cant increases in the frequencies of sperm with chromosomal abnormalities (aneuploidies, structural abnormalities, and prelesions) that can lead to abnormal reproductive outcomes, and that male germ cells differ in their susceptibility to damage. For aneuploidies, induced increases in ejaculated sperm diminish with increasing time after exposure, indicating that cancer patients have only a transient risk for producing abnormal offspring after chemotherapy. However, very few chemotherapeutic agents have been evaluated for chromosomal aberrations and gene mutations in sperm, and further studies are needed for both these sperm end points and others listed in Table 1 .
Our knowledge of the mechanisms underlying the susceptibility differences among types of male germ cells is very limited. There is evidence indicating that the nature of gene mutations is more dependent on the germ cell stage than on the chemical itself ( 42 ) . The time-dependent risks for specifi c types of abnormal reproductive outcomes may differ depending on the type of chemotherapeutic agents employed and time from the end of therapy.
We do not know how many cancer drugs produce transient chromosomal abnormalities in male meiotic and postmeiotic germ cell stages and persistent gene mutations in spermatogonial stem cells. Using the cumbersome animal breeding tests, only a few chemicals have been found to cause mutations in spermatogonial stem cells ( 2 ) . The animal breeding tests show that most mutagens are effective in differentiating germ cells ( Table 2 ) ; namely, spermatocytes and spermatids ( 43 ) . Genetic damage to spermatids is a special case, because genetically damaged spermatids are known to develop into mature sperm that are fully capable of fertilizing eggs despite the presence of DNA damage ( 2 , 32 ) . Taken together, the available data from animal breeding and human sperm studies indicate that it may be ill advised to cryopreserve sperm within the fi rst few weeks after the start of chemotherapy, even though sperm counts and motility are still high. Postponing fertilization for at least 3 months and up to a year following chemotherapy is likely to reduce the risk of fathering an abnormal reproductive outcome ( 44 ) for those agents that do not produce stem cell mutations. Better methods are needed to assess the risk of chemotherapy exposures on mutations in stem cells, because these mutations, if they occur, may persist throughout the reproductive life of the cancer survivor. Modern molecular assays for specifi c gene mutations in sperm, such as those recently applied to age effects in men ( 45 , 46 ) , may provide a new approach to assess susceptibility and persistence in sperm from treated cancer patients.
Although the primary responsibility of the physician is to try to achieve remission and cure, the increasing effectiveness of modern anticancer treatments increases the importance of understanding whether drug regimens can induce elevated frequencies of sperm with gene mutations or chromosomal abnormalities. Furthermore, young cancer survivors and their parents deserve counseling regarding the possibility that chemotherapy may have detrimental effects on the future ability to father healthy progeny, especially for samples obtained within the fi rst few weeks after receiving treatment, when highly susceptible meiotic and postmeiotic cells have progressed to the ejaculate. 
